Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Leonard Resignation Leaves AAM Looking For New Leadership

Gaugh Steps In As Interim CEO Of US Generics And Biosimilars Association

Executive Summary

Dan Leonard has announced his resignation as president and CEO of the US Association for Accessible Medicines. He will be replaced on an interim basis by the group’s vice president for sciences and regulatory affairs, David Gaugh.

You may also be interested in...



PBMs’ ‘Perverse Incentives’ Still Limiting Generics Access, AAM Report Reiterates

Generic medicines continue to be intentionally left off formulary tiers in favor of more expensive brand medications, according to a new report from the US Association for Accessible Medicines.

A Bad Fit: Dan Leonard’s Leadership Style Did Not Translate At AAM

Former employees at the Association for Accessible Medicines detail problems that emerged during Leonard’s tenure, but also say the board of directors must improve its management of the trade organization.

AAM Welcomes CMS Tiers Rule For Generics

A proposed rule set out by the US Centers for Medicare & Medicaid Services directing that generics should be covered on generic tiers has been commended by local off-patent industry group the US Association for Accessible Medicines.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

GB152351

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel